SEATTLE – Integrated Diagnostics (InDi®), an emerging leader in molecular diagnostics, today announced that the company has made substantial progress in its diagnostic programs, triggering a $10 million third tranche of its Series A financing. The company will use the funds to complete clinical development of its in vitro proteomic-based diagnostics programs and prepare for… more

SANTA CLARA, Calif., and SEATTLE, Wash., – Agilent Technologies Inc. (NYSE: A) and Integrated Diagnostics today announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes. Integrated Diagnostics, an emerging leader in molecular diagnostics, is creating large-scale, blood-based molecular diagnostics that leverage advances in proteomics… more

SEATTLE –– Integrated Diagnostics announced today that researchers from the company and the California Institute of Technology (Caltech) will receive a Point-of-Care Diagnostics grant through Grand Challenges in Global Health, an initiative created by the Bill & Melinda Gates Foundation that seeks to engage creative minds across scientific disciplines — including those who have not… more

Protein-Catalyzed Capture Agents (PCCs) Designed Using “Click Chemistry” Show Promise for Broad Use in Diagnostics and Therapeutics Data Demonstrating Synthetic Class of Site-Specific Binding Molecules is Published in the Journal of the American Chemical Society SEATTLE – Integrated Diagnostics, an emerging leader in molecular diagnostics, today announced that it has created a synthetic class of… more

Dr. Barry Sharpless, Nobel Laureate and Click Chemistry Pioneer, Joins Integrated Diagnostics as Advisor SEATTLE – Integrated Diagnostics, an emerging leader in molecular diagnostics, today announced that it has signed a worldwide licensing agreement with The Scripps Research Institute, strengthening its growing network of partners. Under the license, the company will have access to “click… more

Past CFO of Myriad Genetics Joins Preeminent Team at Dr. Lee Hood-Founded Molecular Diagnostics Company SEATTLE – Integrated Diagnostics, an emerging leader in molecular diagnostics founded by Lee Hood, M.D., Ph.D., today announced that Jay Moyes has joined the company’s Board as an independent director. Moyes is the past chief financial officer of Myriad Genetics… more

New CMO to lead rapid development and commercialization of blood-based diagnostics for lung cancer and Alzheimer’s disease SEATTLE – Integrated Diagnostics, an emerging leader in molecular diagnostics founded by Lee Hood, M.D., Ph.D., today announced that Kenneth C. Fang, M.D., has been appointed chief medical officer and vice president of translational research and clinical development…. more

Past President of Myriad Genetic Laboratories Joins Preeminent Team at Dr. Lee Hood-Founded Molecular Diagnostics Company SEATTLE – Integrated Diagnostics, an emerging leader in molecular diagnostics founded by Lee Hood, M.D., Ph.D., today announced that Gregory Critchfield, M.D., M.S., has joined the company’s Board as an independent director. Dr. Critchfield is the past president of… more

Substantial Progress Made in Developing Blood-Based Proteomic Diagnostics; BioTechCube Luxembourg Joins Series A Investors; New Board Member Appointed SEATTLE – Integrated Diagnostics, an emerging leader in personalized diagnostics founded by Dr. Leroy Hood, today announced that the company has made substantial progress, triggering a $10 million second tranche of its Series A financing. The funds… more

Senior Life Sciences Executive Will Lead Emerging Personalized Diagnostics Company Founded by Dr. Leroy Hood SEATTLE – Integrated Diagnostics, a personalized diagnostics company founded by Dr. Leroy Hood, today announced that Dr. Albert Luderer has been appointed by the Board of Directors to serve as CEO. Dr. Luderer was previously president and CEO of BioTrove,… more